Autobahn’s road to a breakthrough depression treatment is paved with high-profile investors

Among the biopharmas eager to find a novel treatment for depression is Autobahn Therapeutics, a San Diego-based biotech with one candidate in the clinic looking at both MDD and bipolar disorder depression. Its lead candidate ABX-002 is a selective thyroid hormone beta receptor agonist that is about to enter phase 2 clinical trials for both indications.